Here, we demonstrate that the application of the Tat-CDK5-CTM peptide, which can effectively disrupt the binding of CDK5 with NR2B and lead to the lysosomal-mediated degradation of CDK5, is protective against stroke damage both in vitro and in vivo. The gene discussed is HSF4; the disease is Stroke.